

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF GLAND PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Gland Pharma Limited** ("the Company"), for the quarter ended June 30, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The comparative financial results of the Company for the quarter ended June 30, 2023 included in the Statement were reviewed by the predecessor auditor, on which they have issued an unmodified conclusion.

Our conclusion on the Statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells**  
Chartered Accountants  
(Firm's Registration Number: 008072S)



**Monisha Parikh**  
Partner

Membership No. 047840

UDIN: 24047840BKFIYY9832



Place: Hyderabad  
Date: August 6, 2024

**GLAND PHARMA LIMITED**

Corporate Identity Number: L24239TG1978PLC002276


Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandhi Maisamma 'X' Roads, D.P. Pally, Dundigal

Dundigal - Gandhi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India

Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.com

**Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2024****(₹ in million)**

Particulars	Quarter ended			Year ended
	30-Jun-24	31-Mar-24	30-Jun-23	31-Mar-24
	Unaudited	Unaudited	Unaudited	Audited
<b>1. Income</b>				
Revenue from operations	10,120.24	11,748.30	8,840.70	41,674.28
Other income	484.90	469.55	352.07	1,666.66
<b>Total income</b>	<b>10,605.14</b>	<b>12,217.85</b>	<b>9,192.77</b>	<b>43,340.94</b>
<b>2. Expenses</b>				
Cost of materials consumed	3,676.87	4,828.80	3,918.01	17,097.40
Purchase of stock-in-trade	65.75	68.28	37.92	231.38
Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,042.58	269.67	(204.90)	874.32
Power and fuel	294.16	289.08	291.63	1,171.95
Employee benefits expense	1,076.77	1,078.66	1,029.09	4,099.45
Depreciation and amortisation expense	408.17	425.63	389.82	1,621.07
Finance costs	9.11	45.34	15.96	78.43
Other expenses	1,028.58	885.51	1,175.33	4,111.97
<b>Total expenses</b>	<b>7,601.99</b>	<b>7,890.97</b>	<b>6,652.86</b>	<b>29,285.97</b>
<b>3. Profit before tax (1-2)</b>	<b>3,003.15</b>	<b>4,326.88</b>	<b>2,539.91</b>	<b>14,054.97</b>
<b>4. Tax expense</b>				
Current tax	762.12	1,006.79	588.80	3,410.20
Deferred tax	11.82	105.98	75.29	246.84
Taxes of earlier years	-	-	-	(35.32)
<b>Total tax expense</b>	<b>773.94</b>	<b>1,112.77</b>	<b>664.09</b>	<b>3,621.72</b>
<b>5. Profit for the quarter/year (3-4)</b>	<b>2,229.21</b>	<b>3,214.11</b>	<b>1,875.82</b>	<b>10,433.25</b>
<b>6. Other comprehensive income</b>				
<i>Items that will not be reclassified subsequently to profit or loss:</i>				
Remeasurement of defined benefit plans	6.21	26.02	7.52	24.86
Deferred tax impact on remeasurement of defined benefit plans	(1.56)	(6.55)	(1.89)	(6.26)
<b>Total other comprehensive (income)/loss, net of tax</b>	<b>4.65</b>	<b>19.47</b>	<b>5.63</b>	<b>18.60</b>
<b>7. Total comprehensive income (5-6)</b>	<b>2,224.56</b>	<b>3,194.64</b>	<b>1,870.19</b>	<b>10,414.65</b>
<b>8. Paid up equity share capital (Face value of ₹1/- each)</b>	<b>164.75</b>	<b>164.71</b>	<b>164.70</b>	<b>164.71</b>
<b>9. Other equity</b>				<b>89,788.18</b>
<b>10. Earnings per share (Face value of ₹1/- each):</b>				
<i>(Not annualised for the quarter)</i>				
Basic (₹)	13.53	19.51	11.39	63.35
Diluted (₹)	13.53	19.51	11.39	63.33



Notes:

1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2024 ("Unaudited Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 6, 2024. The statutory auditors have carried out a limited review on the Unaudited Standalone Financial Results and issued an unmodified report thereon.
2. The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
3. The figures of the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review.
4. The Company is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.
5. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation.
6. The above Unaudited Standalone Financial Results of the Company are available on the Company's website [www.glandpharma.com](http://www.glandpharma.com) and also on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)), where the equity shares of the Company are listed.



For and on behalf of the Board  
**Gland Pharma Limited**

*S. Srinivas*

**Srinivas Sadu**  
**Executive Chairman and CEO**  
DIN No. 06900659

Hyderabad  
August 6, 2024

